The role of dipeptidyl peptidase IV (DP IV) enzymatic activity in T cell activation and autoimmunity

Biological Chemistry

Volumn 383, Issue 7-8, 2002, Pages 1133-1138

  Reinhold, Dirk ^a   Kähne, Thilo ^a   Steinbrecher, Andreas ^a   Wrenger, Sabine ^a   Neubert, Klaus ^a   Ansorge, Siegfried ^a   Brocke, Stefan ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Autoimmune diseases; CD26; Dipeptidyl peptidase IV; T cell activation

Indexed keywords

COLLAGEN; DIAMINE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENZYME INHIBITOR; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; LYMPHOTOXIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; PROTEINASE INHIBITOR;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ARTHRITIS; AUTOIMMUNITY; CELL GROWTH; CLINICAL STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG USE; ENZYME ACTIVITY; ENZYME REGULATION; GRAFT REJECTION; HEART TRANSPLANTATION; HEMATOPOIETIC CELL; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LYMPHOCYTE DIFFERENTIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SHORT SURVEY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANIMAL; ENZYMOLOGY; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; REVIEW;

ANIMALIA;

ANIMALS; ANTIGENS, CD26; AUTOIMMUNITY; HUMANS; LYMPHOCYTE ACTIVATION; PROTEASE INHIBITORS; T-LYMPHOCYTES;

EID: 0036661038     PISSN: 14316730     EISSN: None     Source Type: Journal    
DOI: 10.1515/BC.2002.123     Document Type: Short Survey

References (35)

1. Ansorge, S., Schön, E., and Kunz, D. (1991). Membrane-bound peptidases of lymphocytes: functional implications. Biomed. Biochem. Acta 50, 799-807.
2. Arndt, M., Lendeckel, U., Spiess, A., Faust, J., Neubert, K., Reinhold, D., and Ansorge, S. (2000). Dipeptidyl peptidase IV (DP IV/CD26) mRNA expression in PWM-stimulated T-cells is suppressed by specific DP IV inhibition, an effect mediated by TGF-β1. Biochem. Biophys. Res. Commun. 274, 410-414.
3. Dang, N.H., Torimoto, Y., Deusch, K., Schlossman, S.F., and Morimoto, C. (1990). Comitogenic effect of solid-phase immobilized anti-1F7 on human CD4 T cell activation via CD3 and CD2 pathways. J. Immunol. 144, 4092-4100.
4. De Meester, I., Korom, S., Van Damme, J., and Scharpé, S. (1999). CD26, let it cut or cut it down. Immunol. Today 20, 367-375.
5. Fleischer, B. (1994). CD26: a surface protease involved in T-cell activation. Immunol. Today 15, 180-184.
6. Hanski, C., Huhle, T., and Reutter, W. (1985). Involvement of plasma membrane dipeptidyl peptidase IV in fibronectin-mediated adhesion of cells on collagen. Biol. Chem. Hoppe-Seyler 366, 1169-1176.
7. Hoffmann, T., Reinhold, D., Kähne, T., Faust, J., Neubert, K., Frank, R., and Ansorge, S. (1995). Inhibition of dipeptidyl peptidase IV by anti-DP IV antibodies and non-substrate X-X-Pro-oligopeptides ascertained by capillary electrophoresis. J. Chromatogr. 716, 355-362.
8. Hopsu-Havu, K.V., and Glenner, G.G. (1966). A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-β-naphthylamide. Histochemie 7, 197-201.
9. Ishii, T., Ohnuma, K., Murakami, A., Takasawa, N., Kobayashi, S., Dang, N.H., Schlossman, S.F., and Morimoto, C. (2001). CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO. Proc. Natl. Acad. Sci. USA 98, 12138-12143.
10. Iwata, S., Yamaguchi, N., Munakata, Y., Ikushima, H., Lee, J.F., Hosono, O., Schlossman, S.F., and Morimoto, C. (1999). CD26/dipeptidyl peptidase IV differentially regulates the chemotaxis of T cells and monocytes toward RANTES: possible mechanism for the switch from innate to acquired immune response. Int. Immunol. 11, 417-426.
11. Kähne, T., Lendeckel, U., Wrenger, S., Neubert, K., Ansorge, S., and Reinhold, D., (1999). Dipeptidyl peptidase IV: a cell surface peptidase involved in regulating T cell growth. Int. J. Mol. Med. 4, 3-15.
12. Kameoka, J., Tanaka, T., Nojima, Y., Schlossman, S.F., and Morimoto, C., (1993). Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science 261, 466-469.
13. Korom, S., De Meester, I., Onodera, K., Stadlbauer, T.H.W., Borloo, M., Lambeir, A.M., and Kupiec-Weglinski, J.W. (1997a). The effects of CD26/DPP IV-targeted therapy on acute allograft rejection. Transplant. Proc. 29, 1274-1275.
14. Korom, S., De Meester, I., Stadlbauer, T.H.W., Chandraker, A., Schaub, M., Sayagh, M.H., Belyaev, A., Haemers, H., Scharpé, S., and Kupiec-Weglinski, J.W. (1997b). Inhibition of CD26/Dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients. Transplantation 63, 1495-1500.
15. Korom, S., De Meester, I., Coito, A.J., Graser, E., Pratschke, J., König, S., Grimm, H., Volk, H.D., Scharpé, S., and Kupiec-Weglinski, J.W. (1999). CD26/DPP IV-mediated modulation of acute rejection. Transplant. Proc. 31, 873.
16. Lambeir, A.M., Proost, P., Durinx, C., Bal, G., Senten, K., Augustyns, K., Scharpé, S., Van Damme, J., and De Meester, I. (2001). Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. J. Biol. Chem. 276, 29839-29845.
17. Lojda, Z. (1977). Studies on glycyl-proline naphthylamidase. I. Lymphocytes. Histochemistry 54, 299-309.
18. Pauly, R.P., Rosche, F., Wermann, M., McIntosh, C.H.S., Pederson, R.A., and Demuth, H.U. (1996). Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization time of flight mass spectrometry - a novel kinetic approach. J. Biol. Chem. 271, 23222-23229.
19. Proost, P., Schutyser, E., Menten, P., Struyf, S., Wuyts, A., Opdenakker, G., Detheux, M., Parmentier, M., Durinx, C., Lambeir, A.M., Neyts, J., Liekens, S., Maudal, P.C., Billiau, A. and Van Damme, J. (2001). Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood 13, 3554-3561.
20. Reinhold, D., Bank, U., Bühling, F., Lendeckel, U., Ulmer, A.J., Flad, H., and Ansorge, S. (1994). Transforming growth factor-β1 (TGF-β1) inhibits DNA synthesis of PWM stimulated PBMC via suppression of IL-2 and IL-6 production. Cytokines 6, 382-388.
21. Reinhold, D., Bank, U., Bühling, F., Lendeckel, U., and Ansorge, S. (1995). Transforming growth factor β1 inhibits interleukin-10 mRNA expression and production in pokeweed mitogen-stimulated peripheral blood mononuclear cells and T cells. J. Interferon Cytokine Res. 15, 685-690.
22. Reinhold, D., Bank, U., Bühling, F., Täger, M., Born, I., Faust, J., Neubert, K., and Ansorge, S. (1997a). Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) induces secretion of transforming growth factor-β1 (TGF-β1) in stimulated mouse splenocytes and thymocytes. Immunol. Lett. 58, 29-35.
23. 1 in PWM-stimulated PBMC and T cells. Immunology 91, 354-360.
24. + T cell clones. J. Neuroimmunol. 87, 203-209.
25. Schön, E., Mansfeld, H.W., Demuth, H.U., Barth, A., and Ansorge, S. (1985). The dipeptidyl peptidase IV, a membrane enzyme involved in the proliferation of T lymphocytes. Biomed. Biochem. Acta 44, K9-K15.
26. Schön, E., and Ansorge, S. (1990). Dipeptidyl peptidase IV in the immune system. Cytofluorimetric evidence for induction of the enzyme on activated T lymphocytes. Biol. Chem. Hoppe-Seyler 371, 699-705.
27. Sedo, A., and Malik, R. (2001). Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? Biochem. Biophys. Acta 1550, 107-116.
28. Steinbrecher, A., Reinhold, D., Quigley, L., Gado, A., Tresser, N., Izikson, L., Born, I., Faust, J., Neubert, K., Martin, R., Ansorge, S., and Brocke, S. (2000). Dipeptidyl peptidase IV in inflammatory CNS disease. Adv. Exp. Med. Biol. 477, 145-53.
29. Steinbrecher, A., Reinhold, D., Quigley, L., Gado, A., Tresser, N., Izikson, L., Born, I., Faust, J., Neubert, K., Martin, R., Ansorge, S., and Brodke, S. (2001). Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and upregulates TGF-β1 secretion in vivo. J. Immunol. 166, 2041-2048.
30. Tanaka, S., Murakami, T., Horikawa, H., Sugiura, M., Kawashima, K., and Sugita, T. (1997). Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV. Int. J. Immunopharmacol. 19, 15-24.
31. Tanaka, S., Murakami, T., Nonaka, N., Ohnuki, T., Yamada, M., and Sugita, T. (1998). Anti-arthritic effects of the novel dipeptidyl peptidase IV inhibitors TMC-2A and TSL-225. Immunopharmacology 40, 21-26.
32. Torimoto, Y., Dang, N.H., Vivier, E., Tanaka, T., Schlossman, S.F., and Morimoto, C. (1991). Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes. J. Immunol. 147, 2514-2517.
33. Vivier, I., Marguet, D., Naquet, P., Bonicel, J., Black, D., Xiao-Yan, Li C., Bernard, A.M., Gorvel, J. P., and Pierres, M., (1991). Evidence that thymocyte-activating molecule is mouse CD26 (dipeptidyl peptidase IV). J. Immunol. 147, 447-454.
34. Wrenger, S., Hoffmann, T., Faust, J., Mrestani-Klaus, C., Brandt, W., Neubert, K., Kraft, M., Olek, S., Frank, R., Ansorge, S., and Reinhold, D. (1997). The N-terminal structure of HIV-1 Tat is required for suppression of CD26-dependent T cell growth. J. Biol. Chem. 272, 30283-30288.
35. Wrenger, S., Faust, J., Mrestani-Klaus, C., Fengler, A., Stöckel-Maschek, A., Lorey, S., Kähne, T., Brandt, W., Neubert, K., Ansorge, S., and Reinhold, D. (2000). Down-regulation of T cell activation following inhibition of dipeptidyl peptidase IV/CD26 by the N-terminal part of the thromboxane A2 receptor. J. Biol. Chem. 275, 22180-22186.